Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart stress test aims to diagnose blockages without radiation

NCT ID NCT00894179

Diagnosis Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new stress echocardiography method using regadenoson and atropine to diagnose coronary artery disease. It involved 45 adults scheduled for cardiac catheterization. The goal was to see if this faster, radiation-free approach could accurately detect significant blockages compared to standard angiography.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
regadenoson and atropine
What this could lead to
If successful, this could provide a faster, safer, and radiation-free way to diagnose blocked heart arteries.
What could go wrong
The study was terminated early with only 45 participants, so results are limited and may not apply to everyone. The method may not be as accurate as standard tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Oct 2009

Finished

Apr 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \> 18 years old 2. Able to provide consent 3. Scheduled for cardiac catheterization either with or without a prior functional stress imaging study Exclusion Criteria: 1. Any history of acute myocardial infarction, prior PCI in last 3 months, bypass surgery, 2. History of greater than first degree AV block, sick sinus syndrome in patients 3. Patients with a pacemaker/LBBB 4. History on uncontrolled arrhythmias 5. Patients with significant pulmonary disease, known or suspected bronchoconstrictive or bronchospastic lung disease or other hypersensitivity to adenosine 6. History of cardiac transplantation, hypertrophic cardiomyopathy, acute myocarditis or pericarditis, severe valvular heart disease 7. Hemodynamically unstable patients 8. Dipyridamole use within 30 hours, consumption of methylxanthines (e.g., tea, coffee, caffeinated soft drinks, chocolate, or cocoa) within 12 hours, or use of sublingual nitroglycerin within 2 hours 9. History of glaucoma or obstructive uropathy 10. Allergy or hypersensitivity to atropine 11. Participation in another investigational drug study within 1 month or participation in any previous regadenoson trial 12. Pregnancy, breast feeding, or not using an acceptable method of birth control (if premenopausal) 13. . History of end-stage renal disease on hemodialysis or peritoneal dialysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.